Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Senhwa Announces First Patient Enrolled in Silmitasertib Trial for Severe COVID-19

americanpharmaceuticalreviewJanuary 26, 2021

Tag: Senhwa , COVID-19 , Silmitasertib , BUMCP , IIT

PharmaSources Customer Service